Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 12, 2012, Pages 1830-1844

  Di Maio, Massimo ^a   Leighl, Natasha B ^b   Gallo, Ciro ^c   Feld, Ronald ^b   Ciardiello, Fortunato ^c   Butts, Charles ^d   Maione, Paolo ^e   Gebbia, Vittorio ^f   Morgillo, Floriana ^c   Wierzbicki, Rafal ^g   Favaretto, Adolfo ^h   Alam, Yasmin ⁱ   Cinieri, Saverio ^j   Siena, Salvatore ^k   Bianco, Roberto ^l   Riccardi, Ferdinando ^m   Spatafora, Mario ⁿ   Ravaioli, Alberto ^o   Felletti, Raffaella ^p   Fregoni, Vittorio ^q   Genestreti, Giovenzio ^r   Rossi, Antonio ^e   Mancuso, Gianfranco ^f   Fasano, Morena ^c   Morabito, Alessandro ^a   Tsao, Ming Sound ^b   Signoriello, Simona ^c   Perrone, Francesco ^a   Gridelli, Cesare ^e   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CROSS CANCER INSTITUTE   (Canada)

^e S G MOSCATI HOSPITAL   (Italy)

^f LA MADDALENA CANCER CENTER   (Italy)

^g Durham Regional Cancer Centre   (Canada)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ Centre Regional De Cancerologie De Windsor   (Canada)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k OSPEDALE NIGUARDA CA GRANDA   (Italy)

^l UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^m CARDARELLI HOSPITAL   (Italy)

ⁿ VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^o Civil Hospital   (Italy)

^p UNIVERSITY OF GENOA   (Italy)

^q IRCCS   (Italy)

^r DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

more..

Author keywords

Advanced non small cell lung cancer; Chemotherapy; EGFR; Erlotinib; First line treatment; Health related quality of life; Randomized trial

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PAIN; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DYSPNEA; EXPLORATORY RESEARCH; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP; SYMPTOM; VOMITING;

EID: 84870327842     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318275b327     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
4. Bezjak A, Tu D, Seymour L, et al.; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-3837. (Pubitemid 46630729)
5. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115. (Pubitemid 27021524)
6. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766. (Pubitemid 350002874)
7. Leighl NB, Shepherd HL, Butow PN, et al. Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol 2011;29:2077-2084.
8. Gridelli C, Ciardiello F, Gallo C, et al. First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non- Small-Cell Lung Cancer: The TORCH Randomized Trial. J Clin Oncol 2012;30:3002-3011.
9. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. (Pubitemid 23073154)
10. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-642. (Pubitemid 24164250)
11. Fayers P, Aaronson NK, Bjordal K, et al on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Scoring Manual (2nd ed). EORTC: Brussels, 1999. Pp. 1-77
12. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J; Quality of Life Committee of the NCIC CTG. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280-287. (Pubitemid 40126961)
13. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144. (Pubitemid 28041591)
14. Pintilie M, Competing Risks: A Practical Perspective. Chichester, UK:John Wiley & Sons Ltd, 2007.
15. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
16. Paesmans M. Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer. Curr Opin Oncol 2002;14:389-393. (Pubitemid 34747972)
17. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
18. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-1128.
19. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
20. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
21. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
22. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
23. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.